SmartTRAK interviews two HYFACOL Limited executives about their collagen manufacturing platform, HyFaCol.
Interview Transcript
This is Kris Flinn with SmartTRAK. Today, I am joined by Giuseppe Tronci, lead academic founder and chief scientific officer, and Chris Stephenson, non-executive director from HYFACOL Limited.
HYFACOL is a UK-based spin-out from the University of Leeds. The company has developed HyFaCol, a collagen manufacturing platform that improves the production and quality of medical-grade collagen. A key initial focus is on chronic wound care, with the US skin substitute market worth almost $12 billion in 2025 and currently undergoing a reset following new reimbursement rules. In this interview, we'll discuss the development of the HyFaCol platform, how it's been used on patients, and look at what the future may hold.
Giuseppe and Chris, thank you for joining me today. Can we please start by telling me about HYFACOL as a company and the journey that you've been on?
Giuseppe Tronci: Thank you, Kris. So HYFACOL is a University of Leeds spin-out company that is basically developing a collagen manufacturing technology for skin substitute applications. It builds on more than 10 years of academic research into collagen. And through this phase of development, we have substantially de-risked technology, secured patents in the US and Europe, and also, and most importantly, shown that the products that we are developing enable full closure in animals, and more recently, at least 88% wound closure in pressure ulcers and diabetic foot ulcers in humans. So before going into the commercial phase and the next phase of development, let me perhaps describe a bit more what we have been doing in terms of technology development.
As you know, collagen plays a key role in wound healing in vivo. But when collagen is extracted ...
Click the button below to download and read the full transcript of SmartTRAK Wound GM Kris Flinn’s interview with HYFACOL's Giuseppe Tronci and Chris Stephenson discussing the company’s patented collagen manufacturing platform, HyFaCol, the path to FDA approval and the outcomes of a recent clinical study. 
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
